Navigation Links
Tapered Retractor Blades

ProductsTapered Retractor Blades
Company Schaerer Mayfield USA, Inc.
Item Tapered Retractor Blades
Features 
Description These blades are designed for the retraction of nerves, vessels, tissue, and basal lesions, as well as the brain. Equalizes brain retraction pressure. Decreases shear injury to brain along side edge of retractor. Used in conjunction with the Budde Halo Retractor. Range of blade sizes from 1/4" to 1" wide and 2 mm and 4 mm wide. Quick change and release, malleable material allows preferred contour.
Info Schaerer Mayfield USA, Inc.
Customer Service: (800) 755-6381
Web site: http://www.schaerermayfieldusa.com

Related medicine products :

1. Disposable Bipolar Pencil - 23 Gauge Tapered Tip
2. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
3. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Straight)
4. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 90)
5. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 135)
6. Budde Tapered Retractor Blade Set
7. Greenberg Tapered Retractor Blades
8. LT-Cage Lumbar Tapered Fusion Device
9. Tapered TEFCOR Movable Core Wire Guides
10. Tapered Tefcor Movable Core Wire Guides
11. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 ga. Tapered/Blunt point, Straight)
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products:
(Date:11/21/2008)...- Interoperability pioneer Compressus,Inc. today...ve suite of,Enterprise Systems Integration softwa...TM) System version 2.5. The new release features ...gnificant enhancements to the,Company,s comprehen...ase the,efficiency and automation benefits that m...
(Date:11/21/2008)...irstCall/ -- Vital Images, Inc.,(Nasdaq: VTAL )... analysis,software, and Toshiba Medical Systems C...global distribution agreement for five years, thro...ious agreement, Toshiba will offer Vital Images, s... in more than 50 nations in North and,South Ameri...
(Date:11/21/2008)...wire/ -- In this unstable economic,environment ch...,restructuring, company-wide lay-offs and increas...taining your most-valued customers is the key to,...s - from web interactions,and early warning syste...d,defining the superior customer experience. , ...
(Date:11/21/2008)... always wanted to get cosmetic surgery but either ...cosmetic procedure? A new facelift takes the fear ...t that,s extremely safe, minimally invasive, conve...looking results. What more could you ask for? , ...vember 21, 2008 -- Soluna MD, also known as Soluna...
Breaking Medicine News(10 mins):Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 2Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 3Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 4Health News:Vital Images and Toshiba Renew Distribution Agreement 2Health News:Vital Images and Toshiba Renew Distribution Agreement 3Health News:Creating Brand Advocates by Delivering the Superior Total Customer Experience 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4
...earch Service (ARS) scientists David Ingram and Pa...endations in growing compost tea.// Composting usu..., but new research has found that adding solubles ... rock dust and proprietary nutrient solutions may ...
...ugs used to treat attention deficit hyperactivity ...hiatric side-effects that could manifest as agitat...ued a ruling, despite rare incidences of side-effe...HD, will need to carry new labels with warnings, b...
...ildren to focus more on healthy eating could be ac...ent's compelling towards getting children to eat h...dents.// A $67 million scheme has been unveiled b...oming the obesity problem that threatens to lead t...
...Americans, to the tune of one in six often have tr...em use some alternative medicine or// the other to...n and colleagues from the National Center for Comp... Maryland report in the Archives of Internal Medic...
Other Medicine News:Health News:$67m to Tackle Obesity 2Health News:Sleeping Problems Often Overcome with Alternative medicine 2
(Date:11/21/2008)...D OAKS, Calif., Nov. 21 ...European Committee for Medicinal,Products for Hum...ending,marketing authorisation for Nplate(TM) (ro...recommends Nplate for adult chronic immune (idiopa...ed patients who are refractory to,other treatment...
(Date:11/21/2008)...EAD, England, November 21 /PRNewswire-FirstCall/ -...uropean Committee for Medicinal Products for Human...dation for the approval of Enbrel(R),(etanercept)... and,adolescents with severe plaque psoriasis. If...he Committee,s recommendation, Enbrel will become ...
(Date:11/21/2008)..., N.J., Nov. 21 Ikaria Holdings, I... Company of the Year by the New Jersey Technology ...tion that provides business support, networking op...gy companies and their leaders. Ikaria earned the ...p and unique product/service provision. , , ...
(Date:11/20/2008)...INO, Calif., Nov. 20 Epeius Biotec...II and II studies of Rexin-G in,chemotherapy-resi...oma, as,presented by Dr. Sant P. Chawla, principa...held in London UK on November 13-15, 2008. Patient...r a period up to 9 months. Analysis of,safety and...
Breaking Medicine Technology:Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 2Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 3Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 4Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 5Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 6Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 7Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 8CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2United Therapeutics Reports Third Quarter 2007 Financial Results 1642 1United Therapeutics Reports Third Quarter 2007 Financial Results 1642 2United Therapeutics Reports Third Quarter 2007 Financial Results 1642 3United Therapeutics Reports Third Quarter 2007 Financial Results 1642 4United Therapeutics Reports Third Quarter 2007 Financial Results 1642 5United Therapeutics Reports Third Quarter 2007 Financial Results 1642 6United Therapeutics Reports Third Quarter 2007 Financial Results 1642 7United Therapeutics Reports Third Quarter 2007 Financial Results 1642 8United Therapeutics Reports Third Quarter 2007 Financial Results 1642 9Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 1Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 2Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 3Biopure Announces Pricing of Equity Offering 1638 1Biopure Announces Pricing of Equity Offering 1638 2Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 1Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 2Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 3Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 4Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 5Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 6Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 7Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 8Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 9Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 10Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 11Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 12Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 13Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 14Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 15Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 16
...on-free survival in,the SPARC Phase 3 trial consis... disease progression for patients receiving,satrap...,geographies, as well as presence or absence of pa... -- Pharmion,Corporation and GPC Biotech AG today ... the double-blind, randomized satraplatin Phase,3 ...
...TC 40983 (EPOC),Intergroup Study Results, CHICAGO,...f the,randomized phase III EORTC 40983 Intergroup ...me that peri-operative (pre and post,surgery) FOLF...ation with a standard chemotherapy regimen for col...ven to patients with,resectable liver metastases f...
Other Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9